Aclaris Therapeutics, Inc. - Special Call Transcript
Okay. Good morning, everybody. Welcome to Aclaris' R&D Day. We're excited to walk through kind of the new look of the company since making some strategic decisions over the summer.
So my name is Dr. Neal Walker. I'm the President and CEO of Aclaris. Recently, over the last few months, we decided to undertake a strategic business review, and the output of that review was to divest our commercial and near-term commercial assets and really shift from what we refer to as a fully integrated dermatology company to more of a development-stage biotech company focused primarily on immunology and inflammation.
We did this because we believe we have competitive differentiation in kinase development specifically. We have world-class leadership, as you'll see here today, in the ex-Pfizer kinase development team, and these folks are leaders in cysteinome-based targets, and that -- and we'll talk more about that as we move through the presentation.
Our focus will be on small molecule therapeutics. We
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investorsā 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
